8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Testing of a mobile heating facility to sanitize N-95 respirators against an enveloped respiratory virus

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          In the spring of 2020, the Alaska Native Tribal Health Consortium (ANTHC) designed and built a sanitizing treatment system to address shortages of filtering facepiece respirators (FFRs). The design criteria included sanitizing large numbers of FFRs, repeatedly achieving FFR fit test requirements, and deactivating enveloped respiratory viruses, such as SARS-CoV-2. The outcome was the Mobile Sanitizing Trailer (MST), a 20 by 8-foot modified trailer designed to process up to 1,000 FFRs during a standard heat cycle. This paper reports on the MST’s ability to: (1) sustain a target temperature, (2) produce tolerable conditions for FFRs as measured by fit factor and (3) successfully deactivate an infectious model virus. We found that the MST reliably and uniformly produced 75 degrees Celsius in the treatment chamber for the prescribed periods. Quantitative analysis showed that the FFRs achieved acceptable post-treatment fit factor even after 18, 60-minute heat cycles. Finally, the treated FFR materials had at least a log 3.0 reduction in viral RNA and no viable virus after 30, 60 or 90 minutes of heat treatment. As a sanitizing treatment during supply shortages, we found the MST a viable option for deactivation of virus and extending the usable life of FFRs. 

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV

          Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a novel coronavirus termed SARS-CoV. Due to the severity of this disease, the World Health Organization (WHO) recommends that manipulation of active viral cultures of SARS-CoV be performed in containment laboratories at biosafety level 3 (BSL3). The virus was inactivated by ultraviolet light (UV) at 254 nm, heat treatment of 65 °C or greater, alkaline (pH > 12) or acidic (pH < 3) conditions, formalin and glutaraldehyde treatments. We describe the kinetics of these efficient viral inactivation methods, which will allow research with SARS-CoV containing materials, that are rendered non-infectious, to be conducted at reduced safety levels.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A pandemic influenza preparedness study: use of energetic methods to decontaminate filtering facepiece respirators contaminated with H1N1 aerosols and droplets.

            A major concern among health care experts is a projected shortage of N95 filtering facepiece respirators (FFRs) during an influenza pandemic. One option for mitigating an FFR shortage is to decontaminate and reuse the devices. Many parameters, including biocidal efficacy, filtration performance, pressure drop, fit, and residual toxicity, must be evaluated to verify the effectiveness of this strategy. The focus of this research effort was on evaluating the ability of microwave-generated steam, warm moist heat, and ultraviolet germicidal irradiation at 254 nm to decontaminate H1N1 influenza virus. Six commercially available FFR models were contaminated with H1N1 influenza virus as aerosols or droplets that are representative of human respiratory secretions. A subset of the FFRs was treated with the aforementioned decontamination technologies, whereas the remaining FFRs were used to evaluate the H1N1 challenge applied to the devices. All 3 decontamination technologies provided >4-log reduction of viable H1N1 virus. In 93% of our experiments, the virus was reduced to levels below the limit of detection of the method used. These data are encouraging and may contribute to the evolution of effective strategies for the decontamination and reuse of FFRs. Copyright © 2011 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              COVID-19 Mortality Among American Indian and Alaska Native Persons — 14 States, January–June 2020

              American Indian/Alaska Native (AI/AN) persons experienced disproportionate mortality during the 2009 influenza A(H1N1) pandemic ( 1 , 2 ). Concerns of a similar trend during the coronavirus disease 2019 (COVID-19) pandemic led to the formation of a workgroup* to assess the prevalence of COVID-19 deaths in the AI/AN population. As of December 2, 2020, CDC has reported 2,689 COVID-19–associated deaths among non-Hispanic AI/AN persons in the United States. † A recent analysis found that the cumulative incidence of laboratory-confirmed COVID-19 cases among AI/AN persons was 3.5 times that among White persons ( 3 ). Among 14 participating states, the age-adjusted AI/AN COVID-19 mortality rate (55.8 deaths per 100,000; 95% confidence interval [CI] = 52.5–59.3) was 1.8 (95% CI = 1.7–2.0) times that among White persons (30.3 deaths per 100,000; 95% CI = 29.9–30.7). Although COVID-19 mortality rates increased with age among both AI/AN and White persons, the disparity was largest among those aged 20–49 years. Among persons aged 20–29 years, 30–39 years, and 40–49 years, the COVID-19 mortality rates among AI/AN were 10.5, 11.6, and 8.2 times, respectively, those among White persons. Evidence that AI/AN communities might be at increased risk for COVID-19 illness and death demonstrates the importance of documenting and understanding the reasons for these disparities while developing collaborative approaches with federal, state, municipal, and tribal agencies to minimize the impact of COVID-19 on AI/AN communities. Together, public health partners can plan for medical countermeasures and prevention activities for AI/AN communities. During July 22–September 3, 2020, data were collected on confirmed COVID-19–associated deaths that occurred during January 1–June 30, 2020, from 14 participating states. § These states represent approximately 46.5% of the AI/AN population in the United States. ¶ States provided data on confirmed COVID-19 deaths by two race/ethnicity groups (AI/AN and White), sex (men and women), and 10-year age groups. At the request of the participating tribal epidemiology centers and states, White race was chosen as the sole comparator to avoid comparison of AI/AN persons of other races/ethnicities that have experienced similar COVID-19 health disparities. AI/AN race was defined as AI/AN either alone or in any racial/ethnic combination; White race was defined as non-Hispanic White only.** The workgroup, which included epidemiologists and tribal epidemiology subject matter experts, also collected data on underlying health conditions known to increase risk for severe COVID-19–associated illness; however, incomplete data precluded analysis of underlying health conditions. Data for race, ethnicity, and COVID-19 mortality were obtained by the state health departments from multiple sources, including case investigations, death certificates, and laboratory reports. Age-adjusted and age-specific COVID-19 mortality rates were calculated for AI/AN and White populations. †† The AI/AN and White populations for each state were obtained from 2019 postcensal population estimates §§ and used as the denominator for rate calculations. Death rates by race/ethnicity were age-adjusted to the 2000 U.S. standard population; 95% CIs for rates were calculated using the Byar approximation to the Poisson distribution. COVID-19 death rates among AI/AN were compared with those among White persons using rate ratios. The number of deaths among persons aged <20 years was small (<10), and these data were suppressed to avoid possible harm to AI/AN communities if potentially identifiable data were published. This activity was reviewed by the Council of State and Territorial Epidemiologists and was conducted for public health surveillance purposes consistent with applicable federal law. ¶¶ Participating states reported 1,134 deaths among AI/AN persons and 18,815 deaths among White persons during January 1–June 30, 2020. Men accounted for 621 (55%) AI/AN deaths and 9,775 (52%) deaths in White persons. Overall, AI/AN persons who died from COVID-19 were younger than were White persons: 35.1% of AI/AN COVID-19–associated deaths were among persons aged <60 years, compared with 6.3% of deaths among White persons (Table) (Figure). TABLE COVID-19–associated deaths* among American Indian/Alaska Native (AI/AN) † and non-Hispanic White (White) persons aged ≥20 years, § by demographic characteristics — 14 states, ¶ January–June 2020 Characteristic AI/AN deaths White deaths AI/AN:White rate ratio (95% CI) No. (%)** Rate†† (95% CI) No. (%)§§ Rate†† (95% CI) Total* 1,134 (100) 55.8 (52.5–59.3) 18,815 (100) 30.3 (29.9–30.7) 1.8 (1.7–2.0) Sex* Men 621 (55) 66.4 (60.9–72.1) 9,775 (52) 36.1 (35.4–36.8) 1.8 (1.7–2.0) Women 513 (45) 46.8 (42.8–51.1) 9,035 (48) 25.4 (24.9–26.0) 1.8 (1.7–2.0) Missing 0 — 5 — — Age group, yrs¶¶ 20–29 27 (2) 6.3 (4.2–9.2) 31 (0.2) 0.6 (0.4–0.9) 10.5 (6.3–17.6) 30–39 72 (6) 19.8 (15.5–25.0) 91 (0.5) 1.7 (1.4–2.1) 11.6 (8.5–15.8) 40–49 99 (9) 34.0 (27.6–41.3) 199 (1) 4.1 (3.6–4.7) 8.2 (6.5–10.5) 50–59 200 (18) 73.9 (64.1–84.9) 870 (5) 15.6 (14.6–16.7) 4.7 (4.1–5.5) 60–69 268 (24) 127.7 (112.8–143.9) 2,337 (12) 41.6 (39.9–43.3) 3.1 (2.7–3.5) 70–79 235 (21) 218.1 (191.1–247.8) 4,514 (24) 122.2 (118.7–125.9) 1.8 (1.6–2.0) ≥80 230 (20) 488.3 (427.3–555.7) 10,767 (57) 520.1 (510.3–530.0) 0.9 (0.8–1.1) Missing 3 — 6 — — Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019. * Rates are age-adjusted to the 2000 U.S. standard population. † Includes Hispanic and non-Hispanic AI/AN persons. § Cases in persons aged <20 years suppressed because number was <10. ¶ Alaska, Arizona, Louisiana, Minnesota, Mississippi, Nebraska, New Mexico, New York, North Dakota, Oklahoma, Oregon, South Dakota, Utah, and Washington. ** Includes 12 persons with unknown ethnicity. †† Deaths per 100,000 population. §§ Includes five persons with unknown sex. ¶¶ Rates are age-specific. FIGURE Percentage distribution of COVID-19–associated deaths among American Indian/Alaska Native* and non-Hispanic White persons aged ≥20 years, by age group † — 14 states, § January 1–June 30, 2020 Abbreviation: COVID-19 = coronavirus disease 2019. * Includes Hispanic and non-Hispanic ethnicities. † Percentages by age group are not age-adjusted. § Alaska, Arizona, Louisiana, Minnesota, Mississippi, Nebraska, New Mexico, New York, North Dakota, Oklahoma, Oregon, South Dakota, Utah, and Washington. The figure is a bar graph showing the percentage distribution of COVID-19–associated deaths among American Indians/Alaska Natives and non-Hispanic White persons aged ≥20 years in 14 states, during January 1–June 30, 2020 by age group. The age-adjusted AI/AN COVID-19 mortality rate (55.8 deaths per 100,000) was 1.8 (95% CI = 1.7–2.0) times that among White persons (30.3 deaths per 100,000) (Table). For both AI/AN and White persons, mortality was higher among men (66.4 and 36.1 per 100,000, respectively) than among women (46.8 and 25.4 per 100,000, respectively). Among both AI/AN and White persons, COVID-19 mortality rates increased with age, with the highest age-specific mortality rate among persons aged ≥80 years (488.3 and 520.1 per 100,000, respectively). Mortality rates among AI/AN persons were higher than those among White persons in all age groups except the oldest age group. The largest differences were among persons in the three age groups encompassing 20–49 years. Among persons aged 20–29 years, 30–39 years, and 40–49 years, the COVID-19 mortality rates among AI/AN persons were 10.5, 11.6, and 8.2 times those among White persons, respectively (Table). Discussion In the 14 states that participated in this study, the overall COVID-19 mortality rate among AI/AN persons was higher than that among White persons. This finding is consistent with those from a similar study assessing pandemic influenza A(H1N1)–related mortality ( 1 ). Long-standing inequities in public funding; infrastructure; and access to health care, education, stable housing, healthy foods, and insurance coverage have contributed to health disparities (including higher prevalences of smoking, obesity, diabetes, and cardiovascular disease) that put indigenous peoples at higher risk for severe COVID-19–associated illness ( 4 ). The lack of consistent and complete collection of underlying health conditions prevented the workgroup from assessing the contributions of these conditions to the observed disparity in mortality. This highlights the need for consistent approaches across jurisdictions to collect this information systematically and completely. As with influenza mortality rates, differences in socioeconomic factors might have contributed to elevated COVID-19 mortality ( 5 ). Financial or transportation-related barriers to health care access might have prevented patients from receiving timely medical care at the time of initial evaluation, resulting in more severe illness that was less amenable to treatment ( 2 ). In 2010, the Advisory Committee on Immunization Practices (ACIP) first recommended that vaccination efforts should focus on delivering influenza vaccine to AI/AN population, among others, when supply is limited, based on the disproportionate impact pandemic influenza A(H1N1) had on AI/AN communities during 2009–2010 ( 6 ). The ACIP COVID-19 Vaccines Work Group has developed an ethical framework to guide COVID-19 vaccine allocation decisions when supply is limited ( 7 ), which aims to maximize benefits and minimize harms, promote justice, mitigate health inequities, and promote transparency. Compared with White persons, AI/AN persons have experienced higher morbidity and mortality from COVID-19 ( 3 ).*** Federal, state, tribal, and local partners should consider the AI/AN disparities from COVID-19 and other underlying factors when developing their vaccine allocations strategies. The findings in this report are subject to at least six limitations. First, mortality estimates for other persons of color were not assessed, preventing comparisons with these groups. Second, deaths caused by COVID-19 were likely underreported because of limited testing availability and reluctance to be tested, particularly in the early months of the pandemic ( 8 ). Third, limited completeness and accuracy of race/ethnicity data might lead to undercounting of AI/AN COVID-19–related deaths. AI/AN persons are more likely to be racially misclassified as White or other races in vital records and other data systems, resulting in underestimates of morbidity and mortality in AI/AN communities ( 9 ). Fourth, the inconsistent and incomplete collection of data for underlying health conditions precluded an analysis controlling for underlying health conditions as a factor for COVID-19 mortality. Fifth, the analytic methods used did not account for clustering of deaths by state. Finally, this study reports data from selected states and therefore does not represent the entire AI/AN population within the United States. Despite these limitations, these findings suggest that, compared with the White population, the AI/AN population in the 14 participating states has been disproportionately affected by the COVID-19 pandemic, especially among younger age groups. Improved data quality and completeness for case investigation, death certificates, and laboratory reports can guide decisions on resource prioritization to identify and protect populations at higher risk for illness and death. Public health agencies should engage with tribes through tribal consultations and confer with urban-dwelling AI/AN communities to build upon existing community assets and values to enhance health outcomes. AI/AN communities have formed bidirectional partnerships with public health partners that are rooted in tribal sovereignty and fulfillment of treaty rights to promote culturally sensitive strategies for COVID-19 prevention activities and medical countermeasures ( 10 ). ††† Strategies can draw on cultural factors that include protecting elders and ensuring a healthy future for younger generations. Improving the quality of COVID-19 data will be important for AI/AN communities and their partners to identify populations experiencing excess risk and plan and implement prevention activities and medical countermeasures. Summary What is already known about this topic? COVID-19 incidence is higher among American Indians/Alaska Natives (AI/ANs) than among non-Hispanic Whites. In 2009, AI/ANs experienced disproportionately high pandemic influenza A(H1N1)–associated mortality. What is added by this report? Based on data from 14 participating states, age-adjusted COVID-19–associated mortality among AI/ANs was 1.8 times that among non-Hispanic Whites. Among AI/ANs, mortality was higher among men than among women, and the disparity in mortality compared with non-Hispanic Whites was highest among persons aged 20–49 years. What are the implications for public health practice? AI/ANs have experienced disproportionate rates of infection and mortality during the COVID-19 pandemic. The excess risk, especially for AI/AN males and persons aged 20–49 years, should be considered when planning and implementing medical countermeasures and other prevention activities.
                Bookmark

                Author and article information

                Journal
                Int J Circumpolar Health
                Int J Circumpolar Health
                International Journal of Circumpolar Health
                Taylor & Francis
                1239-9736
                2242-3982
                15 April 2022
                2022
                15 April 2022
                : 81
                : 1
                : 2064597
                Affiliations
                [a ]Department of Community Environment and Health, Community Environment & Health, Alaska Native Tribal Health Consortium (ANTHC); , Anchorage, AK USA
                [b ]Engineering ANTHC; Anchorage, AK, USA
                [c ]Statewide Health Facilities, ANTHC; , Anchorage, AK, USA
                [d ]Department of Biological Sciences, University of Alaska Anchorage (UAA); , Anchorage, AK, USA
                [e ]Community Environment and Health, ANTHC; , Anchorage, AK, USA
                [f ]Director, Department of Standards and Innovation, Standards and Innovation ANTHC; , Anchorage, AK, USA
                [g ]Clinical and Research Services, ANTHC; , Anchorage, AK, USA
                [h ]Dentist, Department of Dental Health Services, Tanana Chiefs Conference; , Fairbanks, AK, USA
                [i ]Department of Biological Sciences, UAA; , Anchorage, AK, USA
                [j ]Director, Internal Medicine, Alaska Native Medical Center; , Anchorage, AK, USA
                Author notes
                CONTACT Michael Brubaker mbrubaker@ 123456anthc.org Community Environment & Health, Alaska Native Tribal Health Consortium (ANTHC); , Anchorage, AK USA

                Affiliations: Alaska Native Tribal Health Consortium, University of Alaska Anchorage, Tanana Chiefs Conference

                The findings and conclusions in this article are those of the author(s) and do not necessarily represent the official position of their associated organisations and institutions.

                Author information
                https://orcid.org/0000-0001-9958-8411
                Article
                2064597
                10.1080/22423982.2022.2064597
                9037215
                35426356
                08768599-f2c0-4db6-bdbd-78cf799a9e85
                © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Figures: 9, References: 20, Pages: 1
                Categories
                Research Article
                Original Research Article

                Medicine
                sars-cov-2,filtering facepiece respirator,reuse,virus inactivation,temperature
                Medicine
                sars-cov-2, filtering facepiece respirator, reuse, virus inactivation, temperature

                Comments

                Comment on this article